A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of 3K3A-APC, a Recombinant Variant of Human Activated Protein C (APC), in Healthy Adult Volunteers
Phase of Trial: Phase I
Latest Information Update: 07 Feb 2018
At a glance
- Drugs 3K3A APC (Primary)
- Indications Amyotrophic lateral sclerosis; Diabetic foot ulcer; Neurological disorders; Septic shock; Stroke
- Focus Adverse reactions
- Sponsors ZZ Biotech
- 13 Feb 2013 Results will be made available in 2013, according to ZZ Biotech.
- 01 Dec 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 15 Aug 2012 New trial record